Redbiotec — a biopharmaceutical company specializing in vaccine development — and GE Healthcare have collaborated to develop a process for the production clarification and concentration of cytomegalovirus-like particles.
A team from Redbiotec used GE Healthcare's single-use WAVE Bioreactor and ReadyToProcess crossflow filtration system to develop the process. The technology has been effectively applied to both in-house and external co-development programs
Redbiotec uses proprietary rePAX® co-expression technology for the efficient generation of multi-component virus-like particles and other protein assemblies.
More articles on GE Healthcare:
GE Healthcare Sees Slight Profit Increase in Q2
Electronic Data Interchange Market to Reach $1.7B by 2018
Hospitals Buying Integrated EMR Solutions for MU Attestatio